NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
6 hedge funds and large institutions have $37.6K invested in NLS Pharmaceutics Warrant in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0.05% more ownership
Funds ownership: 2.5% → 2.55% (+0.05%)
17% less capital invested
Capital invested by funds: $45.4K → $37.6K (-$7.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$719 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$288 |
| 3 |
CS
Clear Street
New York
|
+$4 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $24.5K | – | – | – |
|
|
ACM
2
Altium Capital Management
New York
| $6.88K | – | – | – |
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $4.9K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $612 | +$719 | +12,548 | New |
|
|
CS
5
Clear Street
New York
| $420 | +$4 | +77 | +0.9% |
|
|
6
UBS Group
Zurich,
Switzerland
| $295 | +$288 | +5,023 | +502% |
|
NLSPW Hedge Fund Activity: Q1 2024 in Review
6 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2024, worth a combined $37.6K — down 17% from $45.4K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NLSPW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $719.
- 6 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2024, up from 5 in Q4 2023.
- Funds reported $37.6K of NLS Pharmaceutics Warrant stock for Q1 2024, down 17% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest NLS Pharmaceutics Warrant buyer in Q1 2024 was Susquehanna International Group, an estimated $719 added.
Based on aggregated 13F filings for Q1 2024.